Olema Pharmaceuticals, Inc.
NASDAQOlema Pharmaceuticals heads into its August 14 earnings report carrying one of the heavier short burdens in clinical-stage biotech — and a Street consensus that disagrees sharply with the bears. Short interest is the defining feature of the positioning setup. Nearly one in five freely traded shares — 19.2% of the float — is currently sold short, a figure that has climbed roughly…
Snapshot as of 12 Aug 2026
Olema Pharmaceuticals heads into its August 14 earnings report carrying one of the heavier short burdens in clinical-stage biotech — and a Street consensus that disagrees sharply with the bears. Short interest is the…
OLMA heads into a defining two-week stretch carrying its heaviest short interest in months, a freshly beaten Q1 print, and a key oncology conference on the horizon — all while the stock trades down 13% over the past…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OLMA — free to start on ORTEX.
Sign up for free →Open OLMA on ORTEX